Log In
BCIQ
Print this Print this
 

ImmuTune IMP731

  Manage Alerts
Collapse Summary General Information
Company Prima BioMed Ltd.
DescriptionHuman antibodies against lymphocyte-activation gene 3 (LAG3; CD223)
Molecular Target Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Transplant (unspecified)
Indication DetailsTransplant
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$28.0M

$10.8M

$106.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/17/2014

$28.0M

$10.8M

$7.2M

01/06/2011

Undisclosed

Undisclosed

$99.1M

Get a free BioCentury trial today